Related Experiment Video
Updated: Sep 3, 2025
13:44
Simulation, Fabrication and Characterization of THz Metamaterial Absorbers
Published on: December 27, 2012
15.5K
Experimental Study of a Quad-Band Metamaterial-Based Plasmonic Perfect Absorber as a Biosensor.
Semih Korkmaz1, Evren Oktem2, Ramin Yazdaanpanah3
1Department of Computer Engineering, Bandirma Onyedi Eylul University, Balikesir 10200, Turkey.
Molecules (Basel, Switzerland)
|July 27, 2022
Summary
This study introduces a novel metamaterial perfect absorber (PA) with quad-band resonance for ultrasensitive detection of cancer biomarkers. The plasmonic PA demonstrates near-unity absorption and potential for personalized radiotherapy in brain metastases patients.
Area of Science:
- Metamaterials
- Plasmonics
- Biosensing
Background:
- Metamaterial perfect absorbers (PAs) offer tunable optical properties.
- Plasmonic nanostructures are promising for enhanced light-matter interactions.
- Ultrasensitive detection of cancer biomarkers is crucial for personalized medicine.
Purpose of the Study:
- To design and fabricate a quad-band metamaterial perfect absorber (PA).
- To investigate the biosensing capabilities of the PA for detecting cancer biomarkers.
- To explore the potential application of the PA in point-of-care diagnostics for personalized radiotherapy.
Main Methods:
- Fabrication of a metal-dielectric-metal PA with gold nanoantennas and a MgF2 spacer.
- Numerical and experimental calibration of geometrical parameters for spectral tuning.
- UV-based photochemical immobilization for antibody patterning and biosensing assays.
Main Results:
- The PA exhibits strong quad-band resonances from 1.8 µm to 10 µm.
- Near-unity light absorption was achieved across the targeted spectral range.
- Ultrasensitive detection of a 14 kDa S100A9 antibody biomarker was demonstrated.
Conclusions:
- The developed quad-band plasmonic PA is effective for broadband light absorption.
- The PA shows significant potential for ultrasensitive detection of small cancer biomarkers.
- This technology could enable personalized radiotherapy for brain metastases through point-of-care diagnostics.
